New Castle, Delaware, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Constipation treatment Market by Product Type (Mu-Opioid Receptor Antagonists, Laxative, Chloride Channel-2 Activator, Guanylate Cyclase-C (GC-C) Agonist, And Others), Disease Type (Opioid-Induced Constipation, Chronic Idiopathic Constipation, And Irritable Bowel Syndrome With Constipation), Prescription Type, (Prescribed Drugs and Over-The-Counter Drugs) and Distribution Channel (Online Pharmacy, Drug Store & Retail Pharmacy And Others): Global Opportunity Analysis and Industry Forecast, 2023-2032”. According to the report, the global constipation treatment market was valued for $5.9 billion in 2022 and is estimated to reach $10.1 billion by 2032, exhibiting a CAGR of 5.6% from 2023 to 2032.
Constipation is a condition characterized by infrequent stool passage, often leading to dry, hard, and painful bowel movements. It arises when intestinal muscles fail to efficiently propel waste through the digestive system, resulting in compacted and hard-to-pass stool. Typical constipation symptoms include straining during defecation, feeling of incomplete evacuation, abdominal discomfort, bloating, and reduced bowel movement frequency. Several factors, including insufficient dietary fiber, inadequate fluid consumption, a sedentary way of life, specific medications, and underlying medical issues, can contribute to the onset of constipation.
Request Sample of the Report: https://www.alliedmarketresearch.com/request-sample/8560
Prime determinants of growth
Rise in prevalence of chronic idiopathic constipation, increase in number of geriatric populations suffering from constipation and availability of different drugs for treatment of constipation is anticipated to boost the growth of market. However, alternative options available for treatment of constipation are anticipated to hinder the growth of the market. On the contrary, the high presence of constipation drug providers, increase in prevalence of chronic pain and cancer and rise in usage of opioid is expected to witness growth during the forecast period.
Report coverage & details:
| Report Coverage | Details |
| Forecast Period | 2023–2032 |
| Base Year | 2022 |
| Market Size in 2022 | $5.9 Billion |
| Market Size in 2032 | $10.1 Billion |
| CAGR | 5.6% |
| No. of Pages in Report | 479 |
| Segments covered | Product Type, Disease Type, Prescription Type, Distribution Channel, and Region. |
| Drivers | Rise in prevalence of Chronic disease such as chronic pain and cancer High presence of constipation drug manufacturers Increase in number of geriatric populations |
| Opportunities | Rise in adoption of number of strategies by market players of constipation treatment drugs |
| Restraints | Alternative options available for constipation treatment |
Procure Complete Report at 20% Discount (479 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/constipation-treatment-market
The laxative segment to maintain its leadership status throughout the forecast period.
Based on product type, the laxative segment held the highest market share in 2022, accounting for nearly two-fifths of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to the high presence of market players who manufactures laxatives for constipation treatment. However, the Mu-opioid receptor antagonist segment is projected to manifest significant growth with a CAGR of 6.4% from 2023 to 2032, owing to the increase in prevalence of opioids use disorder and rise in prevalence of chronic pain.
The chronic idiopathic constipation segment to maintain its leadership status throughout the forecast period.
Based on disease type, the chronic idiopathic constipation segment held the highest market share in 2022, accounting for more than half of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in prevalence of chronic idiopathic constipation and increase awareness among the people regarding constipation treatment. However, the opioid-induced constipation segment is projected to manifest a significant CAGR of 6.2% from 2023 to 2032, owing to rising prevalence of opioids use disorder.
The prescribed drugs segment to maintain its leadership status throughout the forecast period.
Based on prescription type, the prescribed drugs segment held the highest market share in 2022, accounting for more than four-fifths of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to increase awareness among the people regarding prescription type constipation treatment. However, the over-the-counter drugs segment is projected to manifest a significant CAGR of 5.9% from 2023 to 2032, owing to increase in adoption of over-the-counter drugs and rise in number of retail pharmacies.
The drug store and retail pharmacy segment to maintain its leadership status throughout the forecast period.
Based on distribution channel, the drug store and retail pharmacy segment held the highest market share in 2022, accounting for more than half of the global constipation treatment market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in adoption of over-the-counter drugs and increase in number of retail pharmacy. However, the online pharmacy segment is projected to manifest a significant CAGR of 6.3% from 2023 to 2032.
For Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/8560
North America to maintain its dominance by 2032.
Based on region, North America held the highest market share in terms of revenue in 2022, accounting for around two-fifths of the global constipation treatment market revenue. This is attributed to the high presence of constipation treatment drug manufacturers in North America and rising prevalence of chronic diseases such as cancer and chronic pain. However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.4% from 2023 to 2032 and is likely to dominate the market during the forecast period, owing to rising number of geriatric populations, as geriatric population is more susceptible to chronic diseases such as constipation, chronic pain and others and increase in awareness among the people regarding constipation treatment.
Leading Market Players: -
- Takeda Pharmaceutical Company Ltd.
- Abbvie Inc.
- Abbott Laboratories
- Sanofi S.A.
- Bausch Health Companies Inc.
- Bayer Ag
- Astrazeneca Plc
- Ironwood Pharmaceuticals, Inc.
- Prestige Consumer Healthcare Inc.
- Ardelyx Inc.
The report provides a detailed analysis of these key players of the global constipation treatment market. These players have adopted different strategies such as agreement, partnership, acquisition, and business expansion to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Browse More Trending Reports in Healthcare Industry By AMR
- The global medical simulation market size was valued at $1,687.50 million in 2020, and is projected to reach $6,688.60 million by 2030
- The global smart pills market was valued at $257 million in 2017, and is expected to reach $650 million by 2025
- The global dialyzer market size was valued at $2,810 million in 2017 and is estimated to reach $4,529 million by 2025
- The global in vitro diagnostics market size was valued at $71,496.16 million in 2020, and is projected to reach $106,914.16 million by 2030
- The global Epilepsy Devices Market Size was valued at $675.23 million in 2021, and is projected to reach $1,112.47 million by 2031
- The Indonesia beauty supplements market size was valued at $170.10 million in 2019, and is projected to reach $355.87 million by 2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
